SB 256-FN (2026): establishing safety and care requirements for clinician-administered drugs.

SB 256-FN (2026)

establishing safety and care requirements for clinician-administered drugs.

• Status: Referred for interim study
• Term: 2025-2026
• House committee: Commerce and Consumer Affairs
• Senate committee: Health and Human Services
• Subject: Public and Mental Health

The Story

It was introduced on January 9, 2025 and referred to the Senate Health and Human Services committee. The committee held a public hearing on February 12, 2025. The committee voted unanimously, 5–0, to recommend that the Senate send it back to committee, and the report was placed on the consent calendar. On March 6, 2025 the Senate voted to send it back to committee on a voice vote. The committee voted unanimously, 5–0, to recommend that the Senate pass it with changes (amendment 2025-3029s), and the report was placed on the consent calendar. The committee's amendment (2025-3029s) was adopted on a voice vote on January 7, 2026, changing the text of the bill. On January 7, 2026 the Senate voted to pass it with changes on a voice vote and ordered it to a third reading. It crossed to the House on February 19, 2026 and was referred to the House Health, Human Services and Elderly Affairs committee. The House withdrew that referral and sent the bill to the Commerce and Consumer Affairs committee instead. The committee held a public hearing on April 7, 2026, with 3 people signed in online: 2 in support and 1 in opposition. The committee held work sessions on April 8, 2026 and April 22, 2026. The committee met in executive session on April 29, 2026 to vote on its recommendation. The committee voted unanimously, 15–0, to recommend that the House study it after the session ends, and the report was placed on the consent calendar. On May 14, 2026 the House voted to study it after the session ends on a voice vote. The committee held work sessions on September 9, 2026 and October 7, 2026. The committee met in executive session on October 14, 2026 to vote on its recommendation. On October 15, 2026 the committee reported back on its interim study of the bill: “Not Recommended for Future Legislation”, by a vote of 11 to 0.

Sponsors

• Sen. Tim McGough (R - SD11) (prime sponsor)
• Sen. Bill Gannon (R - SD23)
• Sen. David Rochefort (R - SD1)
• Rep. John Potucek (R - Rock 13)
• Rep. Julie Miles (R - Hills 12)

Hearings and Sessions

• February 12, 2025, 9:15 AM: hearing, Senate Health and Human Services, LOB 101
• March 6, 2025: consent calendar, Senate
• January 7, 2026: consent calendar, Senate
• April 7, 2026, 2:15 PM: public hearing, House Commerce and Consumer Affairs, GP 159
• April 8, 2026, 10:00 AM: subcommittee work session, House Commerce and Consumer Affairs, GP 229
• April 22, 2026, 10:00 AM: subcommittee work session, House Commerce and Consumer Affairs, GP 229
• April 29, 2026, 10:00 AM: executive session, House Commerce and Consumer Affairs, GP 229
• May 14, 2026: consent calendar, House
• September 9, 2026, 10:00 AM: subcommittee work session, House Commerce and Consumer Affairs, GP 229
• October 7, 2026, 10:00 AM: subcommittee work session, House Commerce and Consumer Affairs, GP 229
• October 14, 2026, 10:00 AM: executive session, House Commerce and Consumer Affairs, GP 229

Votes

• March 6, 2025, Senate: Rereferred to Committee — voice vote, passed
• January 7, 2026, Senate: Ought to Pass with Amendment #2025-3029s — voice vote, passed
• May 14, 2026, House: Refer for Interim Study — voice vote, passed

The Docket

Laws It Would Change

• RSA 420-J

From the General Court

• Bill text
• Bill status page
• Docket
• SC 9
• SC 11
• SJ 1
• HJ 5, pages 124 and 127
• HC 19, page 6
• HJ 13, page 2